基线FDG PET/CT骨骼纹理特征在弥漫性大B细胞淋巴瘤中的诊断与预后价值
研究纳入82例弥漫性大B细胞淋巴瘤患者,评估基线FDG PET骨骼纹理特征对骨髓浸润的诊断与预后价值。ROC分析显示一阶指标SkewnessH诊断骨髓浸润的敏感性和特异性分别为81.8%和81.7%,其预后分层能力优于骨髓活检和PET视觉分析。多因素分析中SkewnessH是无进展生存的唯一独立预测因子。
要点
- SkewnessH诊断骨髓浸润的敏感性81.8%、特异性81.7%。
- SkewnessH对总生存的风险比为3.78(P=0.02),优于骨髓活检和PET视觉分析的2.81(P=0.06)。
- SkewnessH是无进展生存的唯一独立预测因子,总生存的唯一独立预测因子为IPI评分。
核心结论
- 骨骼异质性在整体人群及BMB-/PET-患者中的风险分层能力优于骨髓活检和PET视觉分析,提示其有助于识别诊断上被遗漏的骨髓浸润。
研究设计与样本
- 纳入2008年12月至2015年12月间接受骨髓活检和PET扫描的82例弥漫性大B细胞淋巴瘤患者。
- 两名对骨髓活检结果不知情的阅片者共识视觉评估PET图像判断骨髓浸润,第三名观察者勾画涵盖中轴骨骼和骨盆的感兴趣体积用于评估骨骼纹理特征。
- 采用ROC分析从4个一阶、6个二阶和11个三阶指标中确定诊断骨髓浸润的最佳纹理特征。
主要发现
- 82例患者中22例(26.8%)存在骨髓浸润:13例BMB-/PET+、8例BMB+/PET+、1例BMB+/PET-。
- 9例BMB+患者中,1例经视觉和纹理特征PET评估均判定为不一致的骨髓浸润。
- ROC分析显示一阶指标SkewnessH是识别骨髓浸润的最佳参数,敏感性和特异性分别为81.8%和81.7%。
- SkewnessH对总生存的风险比为3.78(P=0.02),骨髓活检和PET视觉分析为2.81(P=0.06)。
- SkewnessH对无进展生存的风险比为3.17(P=0.03),骨髓活检和PET视觉分析为1.26(P=0.70)。
关键数值与推荐
- SkewnessH诊断骨髓浸润的敏感性81.8%、特异性81.7%。
- SkewnessH对总生存的风险比为3.78(P=0.02),对无进展生存的风险比为3.17(P=0.03)。
- 骨髓活检和PET视觉分析对总生存的风险比为2.81(P=0.06),对无进展生存的风险比为1.26(P=0.70)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to evaluate the diagnostic and prognostic value of skeletal textural features (TFs) on baseline FDG PET in diffuse large B cell lymphoma (DLBCL) patients. METHODS: Eighty-two patients with DLBCL who underwent a bone marrow biopsy (BMB) and a PET scan between December 2008 and December 2015 were included. Two readers blinded to the BMB results visually assessed PET images for bone marrow involvement (BMI) in consensus, and a third observer drew a volume of interest (VOI) encompassing the axial skeleton and the pelvis, which was used to assess skeletal TFs. ROC analysis was used to determine the best TF able to diagnose BMI among four first-order, six second-order and 11 third-order metrics, which was then compared for diagnosis and prognosis in disease-free patients (BMB-/PET-) versus patients considered to have BMI (BMB+/PET-, BMB-/PET+, and BMB+/PET+). RESULTS: Twenty-two out of 82 patients (26.8%) had BMI: 13 BMB-/PET+, eight BMB+/PET+ and one BMB+/PET-. Among the nine BMB+ patients, one had discordant BMI identified by both visual and TF PET assessment. ROC analysis showed that SkewnessH, a first-order metric, was the best parameter for identifying BMI with sensitivity and specificity of 81.8% and 81.7%, respectively. SkewnessH demonstrated better discriminative power over BMB and PET visual analysis for patient stratification: hazard ratios (HR), 3.78 (P = 0.02) versus 2.81 (P = 0.06) for overall survival (OS) and HR, 3.17 (P = 0.03) versus 1.26 (P = 0.70) for progression-free survival (PFS). In multivariate analysis accounting for IPI score, bulky status, haemoglobin and SkewnessH, the only independent predictor of OS was the IPI score, while the only independent predictor of PFS was SkewnessH. CONCLUSION: The better discriminative power of skeletal heterogeneity for risk stratification compared to BMB and PET visual analysis in the overall population, and more specifically in BMB-/PET- patients, suggests that it can be useful to identify diagnostically overlooked BMI.
引用
- Aide N, Talbot M, Fruchart C, et al. Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2017. PMID: 29214417. doi:10.1007/s00259-017-3899-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。